Fluidic Analytics — a company focused on the role of proteins in the biological world — has been issued with a US Patent (9,952,22 B2), paving the way for the development and commercialisation of its next-generation protein analysis technology platform.
Patent
“The issuance of the US Patent for our fluidic separation and detection technology is key to building a platform that we believe will fundamentally change how scientists conduct protein analysis,” said Prof. Tuomas Knowles, chief scientific officer, Fluidic Analytics. “The modular nature of microfluidics makes this technology a foundation on which we can build and support advanced analytical approaches, enabling native state proteins to be easily measured in the lab, clinic or even in the home.”
“We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates,” added Dr Andrew Lynn, chief executive officer, Fluidic Analytics. “Securing the US Patent for our Fluidic Separation and Detection technology is an important step in making this vision a reality. We believe our products, starting with the Fluidity One, will help improve understanding of how proteins behave and inform better decisions about how diseases are diagnosed, treatments are developed and personal well-being is maintained. There is a need for technologies that can characterise proteins in their native state, quickly, and without complex workflows — and that is what we are creating.”
The Fluidic Separation and Detection technology is incorporated into the Fluidity One and combined with an Android based user interface, cloud computing capabilities and disposable microfluidic chips for user experience. Application of the technology will include the analysis of protein quality and understanding protein interactions and aggregation — which are important in fundamental biological research and the development of biopharmaceuticals.